Prolia (denosumab) and Denosumab Biosimilars
Customize your policy alerts
Sign up for all Hawaii Medical Service Association (HMSA) policy alerts
Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage and prior authorization for Prolia and denosumab biosimilar products used for osteoporosis, prevention of osteoporosis, glucocorticoid-induced osteoporosis, and treatment-related bone loss associated with prostate or breast cancer therapy for HMSA Medicare Advantage members.
A preferred product grid and criteria were added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.